INTRODUCTION
duration of 24 months. This regimen continued for at least 12 months after sputum culture conversion. Sputum smear and culture examinations were performed monthly for the first 6 months and then at 2-to 3-month intervals until the end of treatment.
Assessment of Microbiologic Response
Sputum conversion was defined as three consecutive negative cultures within 6 months, with the time of conversion defined as the date of the first negative culture. If the patient could not expectorate sputum during treatment, the sputum was considered to have converted. Sputum relapse was defined as two consecutive positive cultures after sputum conversion (18).
Data Analysis
Because the majority of the data did not follow a normal distribution, all results in the text or tables are expressed as the median and IQR, or as the number (percentage) of patients. Categorical variables were analyzed using the Pearson χ nonparametric repeated-measures analysis of variance (Freidman test) was performed to test for changes in erythrocyte sedimentation rates (ESR) with time.
RESULTS

Patients Characteristics
A total of 65 patients (10 males and 55 females; median age, 55 years ) with M. abscessus lung disease who received combination antibiotic therapy for more than 12 months were included in the study. None of the 65 patients tested positive for human immunodeficiency virus. Baseline characteristics of the patients are summarized in Table 2 . Fifty-seven (88%) patients had a positive AFB smear. Four (6%) patients were either unable to produce sputum or had negative sputum cultures and subsequently underwent bronchoscopy. A diagnosis in these cases was established via culture from bronchial washing or bronchoalveolar lavage. Forty-eight (74%) patients had the nodular bronchiectatic form, 15 (23%) had the upper lobe cavitary form, and 2 (3%) had unclassifiable variants. Female patients were more likely to be non-smoker (100% vs. 30%, P <0.001) and to have nodular bronchiectatic form (84% vs. 20%, P <0.001) compared with male patients. Age and body mass index did not differ significantly between female and male patients. Drug susceptibility tests were performed on M. abscessus isolates recovered from 45 patients as described above. Of the parenteral antibiotics, cefoxitin (98%, 44/45) and amikacin (96%, 43/45) were active against most isolates. Imipenem displayed in vitro activity against a moderate number of isolates (48%, 20/42). Of the oral antibiotics, clarithromycin showed moderate in vitro activity against the isolates (73%, 33/45), but demonstrated better in vitro activity than ciprofloxacin (47%, 21/45).
None of the examined isolates was susceptible to doxycycline (Table 3) .
Combination Antibiotic Treatment
Out of 65 patients, 41 (63%) patients completed the treatment. The median duration of antibiotic treatment was 24.4 months (IQR, 24.2 -24.6 months; Table 4 ).
Thirty-seven patients received antibiotic therapy for 24 months or more. In three patients who underwent surgical resection of localized disease and achieved sputum negative conversion, treatment finished at 13, 19, and 20 months, respectively. One patient, whose sputum cultures had converted to negative for 18 months, refused further therapy at 19 months.
Out of 24 (37%) patients who did not complete the full course of treatment, three patients refused further therapy due to adverse reactions at 15, 15, and 39 months, respectively. Four patients were transferred to another hospital or were lost to follow-up. 
Clinical, Radiographic, and Microbiologic Responses
As shown in Table 5 , response rates were 83% based on symptoms and 74% based on HRCT findings. At the start of treatment, the median ESR was 45.0 mm/hr (IQR, 27.5-73.0 mm/hr). ESR levels decreased to a median of 26.0 mm/hr (IQR, 16.3 -46.5 mm/hr) after an initial 4 weeks of treatments and further decreased to a median of 17.5 mm/hr (IQR, 12.0 -42.0 mm/hr) after 12 months of treatment (P < 0.001).
The initial sputum conversion rate was 72% (47/65), and the median time until sputum conversion was 1 month (IQR, 1 -1 month). The other 18 (28%) patients, including two patients who died of disease progression, failed to achieve sputum conversion. Sputum relapse occurred in nine (19%) of 47 patients who achieved initial
Adjunctive surgical resection
Surgical resection was performed in 14 (22%) patients. The indications for surgery included failure of sputum conversion (n = 6), sputum relapse after initial conversion (n = 2), and complications such as recurrent hemoptysis despite negative sputum conversion (n = 6). Pulmonary resections included lobectomy in six patients, pneumonectomy in three patients, bilobectomy in two patients, segmentectomy in one patient, and lobectomy plus segmentectomy in two patients. Negative sputum culture conversion was achieved within a median duration of 1.5 months (IQR, 1.0-2.0 months) postoperatively and was maintained in seven (88%) of eight patients with preoperative culture-positive sputum.
DISCUSSION
The optimal therapeutic regimen and duration of treatment for M. abscessus In a large study of 154 patients with RGM-associated lung disease, in which more than 80% of patients were infected by M. abscessus, Griffith et al. concluded that M. abscessus was extremely difficult to eradicate by antibiotic therapy (6). However, the patients did not receive the currently recommended combination of antibiotics, which includes newer macrolides such as clarithromycin. The administered drugs included amikacin (58%), cefoxitin (43%), erythromycin (31%), and antituberculosis agents (37%) (6). To our knowledge, there has been no published study for more than 15 years, that has focused on the antibiotic treatment of M. abscessus lung disease in a large sample of patients.
Our study found that a combination antibiotic therapy is modestly effective in producing a favorable microbiologic response. Furthermore, both sputum conversion rates and relapse rates were significantly associated with clarithromycin resistance in this study. ATS/IDSA recommendations suggest that susceptibility to some agents, such as amikacin, cefoxitin, clarithromycin, ciprofloxacin, and doxycycline, should be reported and used to guide treatment (1, 2). However, the relationship between in vitro susceptibility results for M. abscessus and clinical responses to these agents has not been established. Our study results suggest that, for clarithromycin, there is a strong correlation between in vitro and in vivo results. In contrast to clarithromycin, no such relationship was found for amikacin, cefoxitin, ciprofloxacin, or doxycycline in this study.
Our treatment regimen included an initial 4-week regimen of intravenous cefoxitin and amikacin administration. This approach usually requires placement of a long-term indwelling intravenous access with the potential for morbidity. In addition, the administration of intravenous cefoxitin for 4 weeks was frequently associated with adverse reactions such as neutropenia. The incidence of β-lactam antibiotic-induced neutropenia increases when parenteral treatment is used in higher doses and extends beyond 2 weeks (19, 20) . Therefore, these side effects may limit the feasibility of the suggested prolonged treatment duration (i.e., 2−4 months) of parenteral antibiotic therapy, including cefoxitin (1, 2). Imipenem may be a reasonable alternative to cefoxitin (2), but neutropenia can also occur with prolonged administration. We continue to use cefoxitin in the initial 4-week treatment period because of high in vitro susceptibility of M. abscessus isolates to cefoxitin and low reproducibility of susceptibility results for imipenem (1, 2).
For the treatment of M. abscessus lung disease, clarithromycin administration plus at least one other agent to which the organism is susceptible may follow initial therapy. However, this option is limited because of high in vitro resistance rates to the various oral agents used against M. abscessus isolates. We used a clarithromycincontaining three-drug oral regimen because of our concern for the emergence of clarithromycin resistance during clarithromycin monotherapy after discharge from the hospital following the initial 4-week therapy (21, 22) . In addition, the broth microdilution MIC determination method had not yet been established in Korea during the early study period. After the establishment of a reliable drug susceptibility test, we found that the fluoroquinolones, such as ciprofloxacin and moxifloxacin, showed moderate in vitro activity against M. abscessus isolates from patients, whereas doxycycline showed very weak in vitro activity (23). Currently, we are using two-drug regimens including clarithromycin and moxifloxacin after the initial parenteral therapy. abscessus in the present study was referred to the M. abscessus group, which is now divided into three species, M. abscessus, M. massiliense and M. bolletii. Recent studies showed that low MIC of clarithromycin was observed for M. massiliense compared to M. abscessus (37, 38) . In addition, M. bolletii was reported to be naturally resistant to clarithromycin (36, 39). These results suggest that accurate species identification and in vitro clarithromycin susceptibility testing are important for the treatment of lung disease caused by M. abscessus group and treatment outcomes may be different depending on the precise species obtained.
The present study has several limitations. First, our study is a retrospective case study that was conducted at a single center. Treatment regimens cannot be optimized solely on the basis of retrospective studies with limited follow-up data; prospective clinical trials would be the proper approach. Second, the number of sputum specimens collected over time was relatively low. If the sputum samples are examined more frequently, we might find more frequent relapses and earlier ones. Third, bacterial genotyping was not performed in nine patients who became culture positive again after initial sputum conversion. Thus, we are not sure whether the recurrence was due to relapse with the original strain or reinfection with a genetically different strain (40, 41).
Forth, drug susceptibility results were available in only 69% (45/65) of patients. In addition, the inducible macrolide resistance and inducible erm gene, which provide an explanation for the lack of efficacy of macrolide-based treatments (42), were not determined in our study. Most importantly, whether or not a favorable microbiologic response will continue cannot be readily determined. Of the 38 patients who achieved culture-negative sputum for more than 12 months, 32 patients completed their antibiotic therapy and were followed up for only a median of 12 months. This follow-up duration after treatment completion was insufficient to detect sputum relapse in many patients.
Therefore, further follow-up data are essential.
In conclusion, a standardized combination therapy of antibiotics, which includes a clarithromycin-containing drug regimen, along with an initial 4-week course of cefoxitin and amikacin, is moderately effective in treating M. abscessus lung disease.
Negative conversion of sputum was achieved and maintained for more than 12 months in 58% (38/65) of patients. However, frequent adverse reactions and a long duration of hospitalization are problems that remain to be solved. 
